This program will include a discussion of offlabel treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form These data should be considered preliminary until published in a peerreviewed journal ID: 774901
Download Presentation The PPT/PDF document " Guide to Atopic Dermatitis" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Guide to Atopic Dermatitis
Slide2This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.
Slide3Atopic Dermatitis
Slide4What Is Atopic Dermatitis?
Slide5Patient CaseJulien, 43-Year-Old Male
Slide6Patient Case: Julien Assessment and Confirmation of AD
Slide7Patient Case: Julien Identify Degree of Severity
Slide8Assessing SeverityClinical Trial and Practice Setting
Slide9Practical Engagement of the Patient
Slide10When Is Systemic Therapy Appropriate?
Slide11Begin Shared Decision-Making
Slide12Pharmacologic Therapies
Slide13Patient Case (cont)
Slide14Decision 'Tree' Is Dupilumab the Right Choice?
Slide15Defining Treatment Failure
Slide16Insurance Documentation
Slide17Managing Systemic Treatment
Slide18European vs US Access to Dupilumab
Slide19Management Approach to Pediatric Patients
Slide20Supporting Pediatric PatientsParental Education
Slide21Concluding Remarks
Slide22Abbreviations